Skip to main content
TipRanks
Go Ultimate75% OFF

AstraZeneca (AZN) Drug Pipeline

664 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Durvalumab, Flot ChemotherapyEsophagogastric Junction, GastricPhase IIIRecruitingA Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.Sep 15, 2026―
Bevacizumab, Torvutatug Samrotecan, Azd5335Epithelial Ovarian CancerPhase IIIRecruitingTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian CancerSep 15, 2026―
Bevacizumab, Torvutatug Samrotecan, Azd5335Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, Platinum-Sensitive Relapsed Fallopian Tube Cancer, Platinum-Sensitive Relapsed Primary Peritoneal CancerPhase IIIRecruitingTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerSep 07, 2026
Azd0543Human Metapneumovirus InfectionPhase IRecruitingStudy of Safety and PK of AZD0543 in Healthy AdultsAug 28, 2026
ElecoglipronObesity, OverweightPhase IIIRecruitingA Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusAug 17, 2026
Azd6234Obesity Or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2Phase IIIRecruitingA Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusAug 10, 2026
Lenbelintide, Azd6234Obesity Or Overweight, Diabetes Mellitus, Type 2Phase IIIRecruitingA Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightAug 06, 2026
Lenbelintide, Azd6234Obesity Or OverweightPhase IIIRecruitingA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusAug 05, 2026
Lenalidomide, Cyclophosphamide, Azd0120, Fludarabine, MelphalanNewly Diagnosed Multiple Myeloma (Ndmm)Phase IIIRecruitingA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Jul 22, 2026
AnifrolumabLupus Erythematosus, SystemicPhase IIIRecruitingA Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusJul 21, 2026

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does AstraZeneca plc (AZN) have in its pipeline
AstraZeneca AZN is currently developing the following drugs: Durvalumab, Flot Chemotherapy, Bevacizumab, Torvutatug Samrotecan, Azd5335, Azd0543, Elecoglipron, Azd6234, Lenbelintide, Azd6234, Lenalidomide, Cyclophosphamide, Azd0120, Fludarabine, Melphalan, Anifrolumab, Elecoglipron Reference Formulation Dose A, Elecoglipron Test Formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test Formulation 1 Dose B, Elecoglipron Test Formulation 2 Dose A, Elecoglipron Test Formulation 2 Dose B, Absk043 In Combination With Osimertinib, Saruparib, Enzalutamide, Darolutamide, Abiraterone, Balcinrenone/Dapagliflozin, Azd6489, Licensed Rsv Vaccine #1, Licensed Rsv Vaccine #2, Azd4144, Itraconazole, Daratumumab, Azd4045, Aldesleukin, Trastuzumab Deruxtecan, Trastuzumab, Palbociclib, Endocrine Therapy, Pertuzumab, T-Dxd, Enhertu, Herceptin, Ibrance, Azd0292, Semaglutide, Elecoglipron, Dapagliflozin, Elecoglipron, Anifrolumab + Apfs, Medi-546, Dapagliflozin, Balcinrenone/Dapagliflozin, Laroprovstat/Ezetimibe Fcdp, Laroprovstat Stp, Ezetimibe Stp, Laroprovstat/Ezetimibe Fcdp-Slow Variant, Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Azd7760, Eplontersen, Alxn2220, Camizestrant, Ribociclib, Azd9833, Docetaxel, Azd9574, Azd2287, Azd2265, Azd8965 Low Dose, Azd8965 Medium Dose, Azd8965 High Dose, Azd2389, Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2, Enzalutamide, Darolutamide, Azd2265, Cabazitaxel, Abiraterone, Apalutamide, Radium-223, Rezvilutamide, Zytiga, Rosuvastatin, Atorvastatin, Elecoglipron, Azd8359. These drug candidates are in various stages of clinical development as the company works toward FDA approval.